Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates

Kyle LaHucik

Senior Reporter

AI drug discovery and development company Exscientia is stopping a solid tumor trial as it refocuses its internal pipeline amid plans to ink another partnership …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates